<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.139440.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Case Report</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Case Report: Fever of unknown origin caused by type &#x2161;&#x00a0;lepra reaction</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 1 approved, 1 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Ran</surname>
                        <given-names>Xiaojuan</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-2968-2597</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Ma</surname>
                        <given-names>Ke</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Wang</surname>
                        <given-names>Yanxia</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Wu</surname>
                        <given-names>Yayun</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Department of Infectious Diseases, The Affiliated Hospital, Guizhou Medical University, Guiyang, Guizhou, 550001, China</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:gzwu56861@163.com">gzwu56861@163.com</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>13</day>
                <month>11</month>
                <year>2023</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2023</year>
            </pub-date>
            <volume>12</volume>
            <elocation-id>1459</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>28</day>
                    <month>7</month>
                    <year>2023</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Ran X et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/12-1459/pdf"/>
            <abstract>
                <p>We report an ethnic minority patient presenting as fever of unknown origin for over 25 days, who was admitted with atypical cutaneous lesions, damages in the peripheral joints and nervous system. Owing to tracing the past medical history, the patient has received a prompt diagnosis and achieved good outcome. By summarizing the entire diagnosis and treatment process, we report the case to deepen the understanding of fever of unknown origin caused by type &#x2161; lepra reaction. All specialties, meanwhile, should be aware of the rare infectious diseases in daily medical practice.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>fever of unknown origin</kwd>
                <kwd>lepra reaction</kwd>
                <kwd>leprosy</kwd>
                <kwd>case report</kwd>
                <kwd>cutaneous</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>A fever of unknown origin (FUO) is defined as an unexplained fever of 38.3 &#x00b0;C or higher for at least three weeks&#x2019; duration after preliminary investigations.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> In general, infection is the primary cause of FUO, which accounts for approximately one-fourth, followed by neoplasm and noninfectious inflammatory diseases.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup>
            </p>
            <p>Leprosy, known also as Hansen&#x2019;s disease, is a chronic granulomatous disease caused by the intracellular bacterium 
                <italic toggle="yes">Mycobacterium leprae</italic> (
                <italic toggle="yes">M. leprae</italic>). 
                <italic toggle="yes">M. leprae</italic> often spreads by respiratory droplets and close contact and can involve multiple systems throughout the body, especially the nervous, integumentary and musculoskeletal system, whi ch are misdiagnosed as arthritis. Moreover, lepra reaction developed from leprosy responds for a significant morbidity and mortality without relationship to the timing of treatment, despite effective measures counteract the causative 
                <italic toggle="yes">M. leprae</italic> with antibiotics.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> It is regretful that the underlying mechanism of lepra reaction is still poorly understood.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> With development of medical technology and improvement of sanitary conditions, the World Health Organization set a goal of reducing leprosy prevalence to less than 1 per 10,000 inhabitants from 2000 to 2005.
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup>
            </p>
            <p>In this report, a case of fever of unknown origin was eventually identified as type II lepra reaction with the aid of Institute for Dermatologic Diseases Control and Prevention. Due to the prompt intervention, the patient has achieved recovery. The purpose of this case report is to remind clinicians to be familiar with and to detect early for lepra reactions.</p>
        </sec>
        <sec id="sec2">
            <title>Case presentation</title>
            <p>A 41-year-old male, who is a minority mainly distributed in Guizhou Province, presented as intermittent fever with body temperature exceeding 39 &#x00b0;C over 16 days, accompanying ring-shaped febrile rash, swelling, pain and deformity of the extremities, was transferred to hospitalization from outpatient. The patient denied a family history or special occupational exposures, with long-term irregular glucocorticoids (prednisone acetate) medication history.</p>
            <p>On admission, physical examination revealed facial flush with sparse eyebrows, enlargement of left cervical and inguinal lymph nodes, acromegaly along with eagle talon-shaped deformity of both hands, soft subcutaneous masses, skin keloid scar and concomitant pigmentation (shown in 
                <xref ref-type="fig" rid="f1">Figure 1</xref>). Laboratory examination showed an abnormal haemograms including WBC count 11.58&#x00d7;10
                <sup>9</sup>/L, neutrophil percentage 79.70%, ESR 38mm/h, Interleukin-6 31.77 pg/ml, PCT 0.26 ng/ml, plasma CRP 165 mg/L. Subcutaneous masses of right elbow joint were detected by ultrasonography, considering to be olecranon bursitis (shown in 
                <xref ref-type="fig" rid="f2">Figure 2</xref>). According to all results at the present stage, a diagnosis of acute infection could not be ruled out, followed by an antimicrobial agent treatment using cefoperazone-sulbactam (2 g, q12h) and levofloxacin (0.5 g, qd) for 3 days and switching to a broad antibacterial spectrum combination of meropenem (1 g, q8h) and vancomycin (15 mg/kg, q12h) for extra 3 days.</p>
            <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                <label>Figure 1. </label>
                <caption>
                    <title>Photographs of physical examination.</title>
                    <p>A. Facial flush with spare eyebrows. B. Subcutaneous mass of right elbow joint. C. Aagle talon-shaped deformity of right hand. D-E. Acromegaly along with skin keloid scar and concomitant pigmentation.</p>
                </caption>
                <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152716/a045fec0-6926-4fc4-8791-8a8d1c15e1f3_figure1.gif"/>
            </fig>
            <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                <label>Figure 2. </label>
                <caption>
                    <title>Ultrasonography of the right upper limb.</title>
                    <p>A-B. Hyperechoic mass in the right elbow joint without apparent blood flow signal. C-D. Effusion accumulation at the periphery of right hand tendons.</p>
                </caption>
                <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152716/a045fec0-6926-4fc4-8791-8a8d1c15e1f3_figure2.gif"/>
            </fig>
            <p>During anti-infection and supportive treatment, there were no marked improvements in the symptoms. In parallel, further MRI of both ankle and knee joints demonstrated old mechanical injuries shown as cruciate ligament and meniscal damage and soft-tissue edema, excluding suspicious infection foci (shown in 
                <xref ref-type="fig" rid="f3">Figure 3</xref>). No significant abnormalities were found in subsequent comprehensive clinical examinations for FUO, such as cranial and chest-abdomen CT, blood culture, echocardiography and bone marrow biopsy. Note, electromyography investigation suggested peripheral nerve injury, particularly peroneal nerve motor conduction block.</p>
            <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                <label>Figure 3. </label>
                <caption>
                    <title>MR imaging of both knee and ankle joints with periarticular edema and effusions, concomitantly old mechanical injuries of meniscus and ligaments.</title>
                    <p>A-D figures represent left knee joint, left ankle joint, right knee joint, and right ankle joint.</p>
                </caption>
                <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152716/a045fec0-6926-4fc4-8791-8a8d1c15e1f3_figure3.gif"/>
            </fig>
            <p>In order to specify the reason of FUO, evaluation of a detailed history and physical examination were carefully performed by superior physician again. Some clinical signs and manifestations, for example, spare eyebrows, skin lesions, and peripheral nerve injury, came into view, referring to a leprosy. We immediately contacted the Institute for Dermatologic Diseases Control and Prevention of Guizhou province and applied for a detection of 
                <italic toggle="yes">M. leprae</italic> in tissue fluid of the patient. Although repeated multiple testing of 
                <italic toggle="yes">M. leprae</italic> staining were negative, an inspiring diagnostic clue, over 10-year leprosy history of this patient, was probed out from previous archive of the institute. Based on the abovementioned information, fever of unknown origin caused by type II lepra reaction would be regarded as this patient&#x2032;s final diagnosis. Here, we took the targeted intervention measures, mainly a combination of prednisone acetate (40 mg, qd) and thalidomide (50 mg, qid), in accordance to current treatment guidelines.
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> After receiving treatment, the patent&#x2032;s symptoms were soon relieved without any adverse events and indicators of lepra reaction-related (ESR, Il-6, CRP, ect.) returned to normal level. The patient gradually recovered, and was discharged after nearly a month of admission.</p>
        </sec>
        <sec id="sec3" sec-type="discussion">
            <title>Discussion</title>
            <p>FUO remains an intractable diagnostic and therapeutic problem in clinical daily practice, though medical technologies have undergone rapid development. Data available from published papers, infectious disease is the main reason of FUO in fact. For many pathogenic microorganisms are difficulty to identify, definite diagnose of infection and pathological changes will hardly be verified in the early stage.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup>
            </p>
            <p>Leprosy is uncommon or rare in China, therefore, current infection and lepra reaction of leprosy are easy to overlook by clinicians. Besides, the pathogenesis of leprosy is not quite clear yet, which poses a huge challenge to physicians. Previous studies have indicated more than one-half had lepra reaction of leprosy, even many years after cessation of the treatment, which is associated with heredity, chronic infections and autoimmune disorders.
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup> Lepra reaction can be classified into two types. Type I lepra reaction is a delayed, cell-mediated response mainly characterized by cutaneous lesions and neuritis, especially the intense pain in the affected joints, while fever and haematological abnormalities were uncommon.
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> On another scale, erythema nodosum leprosum (ENL) also called type II lepra reaction is a severe systemic immune-mediated complication of borderline and lepromatous leprosy, which is a prototypic antibody response to antigens with histopathological alterations of allergic vasculitis.
                <sup>
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup> An apparent discrepancy of type I lepra reaction patients with skin ulceration, ENL patients usually exhibit erythema nodosum, subcutaneous hypersensitivity reaction, lymphadenitis and interstitial tissue edema, presenting with both fever and abnormal blood index, such as increased neutrophilia, macroglobulin (IgG, IgM), complement 3 (C3) and 2 (C2).
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup> In addition, cytokine detections may provide important basis for the diagnosis and treatment of patients with type II lepra reaction in terms of the clinical researches.
                <sup>
                    <xref ref-type="bibr" rid="ref13">13</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup> Taking into account the leprosy and long-term irregular glucocorticoids medication history, existing diagnosis of FUO, excluding of acute infection by negative results of 
                <italic toggle="yes">M. leprae</italic> staining and MRI, we would consider type II lepra reaction as final diagnosis and started on symptomatic treatment by a combination of prednisone acetate and thalidomide.</p>
            <p>The patient&#x2019;s rapid rehabilitation further confirmed the diagnosis of type II lepra reaction. During the combined drug use procedure, patient developed no adverse reactions with good adherence. The favorable outcome of this patient was consistent with the reported literature,
                <sup>
                    <xref ref-type="bibr" rid="ref15">15</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> owing to prompt differential diagnosis and treatment-adjusted. We have been inspired by the present case and draw some insight that clinicians should obtain a comprehensive history, physical examination and laboratory evaluation for each patient suspected of having FUO, as well as enhance diagnostic competency for rare infectious diseases in the absence of clear and unequivocal medical history.</p>
            <p>The studies ethics committee approval and fully informed written consent.</p>
            <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.</p>
        </sec>
        <sec id="sec4">
            <title>Consent</title>
            <p>Written informed consent was obtained from the patient and his family for publication of this case report and accompanying images.</p>
        </sec>
    </body>
    <back>
        <sec id="sec7" sec-type="data-availability">
            <title>Data availability</title>
            <p>No data are associated with this article.</p>
        </sec>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wright</surname>
                            <given-names>WF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mulders-Manders</surname>
                            <given-names>CM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Auwaerter</surname>
                            <given-names>PG</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Fever of Unknown Origin (FUO)-A Call for New Research Standards and Updated Clinical Management.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Med.</italic>
</source>
                    <year>2022</year>;<volume>135</volume>(<issue>2</issue>):<fpage>173</fpage>&#x2013;<lpage>178</lpage>.
                    <pub-id pub-id-type="pmid">34437835</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.amjmed.2021.07.038</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Haidar</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>N</given-names>
                        </name>
</person-group>:
                    <article-title>Fever of Unknown Origin.</article-title>
                    <source>

                        <italic toggle="yes">N. Engl. J. Med.</italic>
</source>
                    <year>2022</year>;<volume>386</volume>(<issue>5</issue>):<fpage>463</fpage>&#x2013;<lpage>477</lpage>.
                    <pub-id pub-id-type="doi">10.1056/NEJMra2111003</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Amorim</surname>
                            <given-names>FM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nobre</surname>
                            <given-names>ML</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nascimento</surname>
                            <given-names>LS</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.</article-title>
                    <source>

                        <italic toggle="yes">PLoS Negl. Trop. Dis.</italic>
</source>
                    <year>2019</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e0007089</fpage>.
                    <pub-id pub-id-type="pmid">30689631</pub-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pntd.0007089</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6366718</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Scollard</surname>
                            <given-names>DM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Martelli</surname>
                            <given-names>CM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Stefani</surname>
                            <given-names>MM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Risk factors for leprosy reactions in three endemic countries.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Trop. Med. Hyg.</italic>
</source>
                    <year>2015</year>;<volume>92</volume>(<issue>1</issue>):<fpage>108</fpage>&#x2013;<lpage>114</lpage>.
                    <pub-id pub-id-type="pmid">25448239</pub-id>
                    <pub-id pub-id-type="doi">10.4269/ajtmh.13-0221</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4347363</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ebenezer</surname>
                            <given-names>GJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Scollard</surname>
                            <given-names>DM</given-names>
                        </name>
</person-group>:
                    <article-title>Treatment and Evaluation Advances in Leprosy Neuropathy.</article-title>
                    <source>

                        <italic toggle="yes">Neurotherapeutics.</italic>
</source>
                    <year>2021</year>;<volume>18</volume>(<issue>4</issue>):<fpage>2337</fpage>&#x2013;<lpage>2350</lpage>.
                    <pub-id pub-id-type="pmid">34799845</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s13311-021-01153-z</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8604554</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Boushab</surname>
                            <given-names>BM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fall-Malick</surname>
                            <given-names>FZ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Basco</surname>
                            <given-names>LK</given-names>
                        </name>
</person-group>:
                    <article-title>Two Cases of Delayed Diagnosis of Leprosy in Mauritania.</article-title>
                    <source>

                        <italic toggle="yes">Case Rep. Dermatol. Med.</italic>
</source>
                    <year>2018</year>;<volume>2018</volume>:<fpage>1</fpage>&#x2013;<lpage>4</lpage>.
                    <pub-id pub-id-type="doi">10.1155/2018/4394297</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Mungroo</surname>
                            <given-names>MR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>NA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Siddiqui</surname>
                            <given-names>R</given-names>
                        </name>
</person-group>:
                    <article-title>Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options.</article-title>
                    <source>

                        <italic toggle="yes">Microb. Pathog.</italic>
</source>
                    <year>2020</year>;<volume>149</volume>:<fpage>104475</fpage>.
                    <pub-id pub-id-type="pmid">32931893</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.micpath.2020.104475</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Fusco</surname>
                            <given-names>FM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pisapia</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nardiello</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Fever of unknown origin (FUO): which are the factors influencing the final diagnosis? A 2005-2015 systematic review.</article-title>
                    <source>

                        <italic toggle="yes">BMC Infect. Dis.</italic>
</source>
                    <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>653</fpage>.
                    <pub-id pub-id-type="pmid">31331269</pub-id>
                    <pub-id pub-id-type="doi">10.1186/s12879-019-4285-8</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6647059</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Scollard</surname>
                            <given-names>DM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Martelli</surname>
                            <given-names>CM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Stefani</surname>
                            <given-names>MM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Risk factors for leprosy reactions in three endemic countries.</article-title>
                    <source>

                        <italic toggle="yes">Am. J. Trop. Med. Hyg.</italic>
</source>
                    <year>2015</year>;<volume>92</volume>(<issue>1</issue>):<fpage>108</fpage>&#x2013;<lpage>114</lpage>.
                    <pub-id pub-id-type="pmid">25448239</pub-id>
                    <pub-id pub-id-type="doi">10.4269/ajtmh.13-0221</pub-id>
                    <pub-id pub-id-type="pmcid">PMC4347363</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jha</surname>
                            <given-names>AK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zeeshan</surname>
                            <given-names>MD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tiwary</surname>
                            <given-names>P</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Dermoscopy of Type 1 Lepra Reaction in Skin of Color.</article-title>
                    <source>

                        <italic toggle="yes">Dermatol. Pract. Concept.</italic>
</source>
                    <year>2020</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e2020083</fpage>.
                    <pub-id pub-id-type="pmid">32642318</pub-id>
                    <pub-id pub-id-type="doi">10.5826/dpc.1003a83</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Negera</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Walker</surname>
                            <given-names>SL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bobosha</surname>
                            <given-names>K</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>T-cell regulation in Erythema Nodosum Leprosum.</article-title>
                    <source>

                        <italic toggle="yes">PLoS Negl. Trop. Dis.</italic>
</source>
                    <year>2017</year>;<volume>11</volume>(<issue>10</issue>):<fpage>e0006001</fpage>.
                    <pub-id pub-id-type="pmid">28991896</pub-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pntd.0006001</pub-id>
                    <pub-id pub-id-type="pmcid">PMC5648259</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Amorim</surname>
                            <given-names>FM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nobre</surname>
                            <given-names>ML</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nascimento</surname>
                            <given-names>LS</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.</article-title>
                    <source>

                        <italic toggle="yes">PLoS Negl. Trop. Dis.</italic>
</source>
                    <year>2019</year>;<volume>13</volume>(<issue>1</issue>):<fpage>e0007089</fpage>.
                    <pub-id pub-id-type="pmid">30689631</pub-id>
                    <pub-id pub-id-type="doi">10.1371/journal.pntd.0007089</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6366718</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zaky</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Obaid</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khedr</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Implications of Serum Anti-Ceramide Antibodies and Interleukin 4 on Nerve Damage and Physical Impairments Among Leprotic Patients: A Case-Controlled Study.</article-title>
                    <source>

                        <italic toggle="yes">J. Drugs Dermatol.</italic>
</source>
                    <year>2022</year>;<volume>21</volume>(<issue>3</issue>):<fpage>284</fpage>&#x2013;<lpage>291</lpage>.
                    <pub-id pub-id-type="pmid">35254767</pub-id>
                    <pub-id pub-id-type="doi">10.36849/JDD.5543</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Polycarpou</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Walker</surname>
                            <given-names>SL</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lockwood</surname>
                            <given-names>DN</given-names>
                        </name>
</person-group>:
                    <article-title>A systematic review of immunological studies of erythema nodosum leprosum.</article-title>
                    <source>

                        <italic toggle="yes">Front. Immunol.</italic>
</source>
                    <year>2017</year>;<volume>8</volume>(<issue>8</issue>):<fpage>233</fpage>.</mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Goulart</surname>
                            <given-names>IMB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Santana</surname>
                            <given-names>MAO</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Costa</surname>
                            <given-names>WVTD</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Type 2 leprosy reaction presenting as a monoarthritis post multidrug therapy.</article-title>
                    <source>

                        <italic toggle="yes">IDCases.</italic>
</source>
                    <year>2022</year>;<volume>27</volume>:<fpage>e01386</fpage>.
                    <pub-id pub-id-type="pmid">35036324</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.idcr.2022.e01386</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8749206</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Bhat</surname>
                            <given-names>RM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Vaidya</surname>
                            <given-names>TP</given-names>
                        </name>
</person-group>:
                    <article-title>What is new in the pathogenesis and management of erythema nodosum leprosum.</article-title>
                    <source>

                        <italic toggle="yes">Indian Dermatol. Online J.</italic>
</source>
                    <year>2020</year>;<volume>11</volume>(<issue>4</issue>):<fpage>482</fpage>&#x2013;<lpage>492</lpage>.
                    <pub-id pub-id-type="pmid">32832433</pub-id>
                    <pub-id pub-id-type="doi">10.4103/idoj.IDOJ_561_19</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7413435</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report257374">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.152716.r257374</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Dewi</surname>
                        <given-names>Dian Andriani Ratna</given-names>
                    </name>
                    <xref ref-type="aff" rid="r257374a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-9541-2790</uri>
                </contrib>
                <aff id="r257374a1">
                    <label>1</label>The Republic of Indonesia Defense University, Bogor, Indonesia</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>5</day>
                <month>6</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Dewi DAR</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport257374" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.139440.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This work is of high quality and significantly contributes to the literature. Leprosy is a neglected tropical disease, so the immunopathogenesis of leprosy is very interesting. Early indications of leprosy are challenging to identify in Tiongkok because the disease is very rare.</p>
            <p> Increased signs and symptoms of leprosy, known as leprosy reactions, are a serious concern. These reactions, if ignored or treated incorrectly, can cause severe neurological dysfunction and subsequent disability. Leprosy reactions, especially type 1 and type 2, are a significant cause of nerve injury and the development of incurable conditions, posing long-lasting obstacles to current leprosy eradication efforts. In this case, thanks to assistance from the Institute for Dermatologic Diseases Control and Prevention, the fever of unknown cause (FUO) suffered by the patient was finally determined to be a type II leprosy reaction.</p>
            <p> The main obstacle in providing care for leprosy patients is developing "reactions." The reactions listed above are caused by the intricate immune response to M. leprae, which might appear before, during, or after multidrug treatment (MDT) administration. Two main classifications can be identified for leprosy reactions (LRs). Type 1 leprosy reaction (T1LR), commonly referred to as a "reversal" reaction, is classified as a type IV hypersensitivity reaction. The reaction described above is frequently found in individuals who have been diagnosed with borderline leprosy (BL). This condition is defined by a cellular immune response targeted explicitly towards specific antigens of the M. leprae bacteria [Ref -1]. The distinguishing characteristic of T1LR is the sudden onset of acute inflammation in preexisting cutaneous lesions or the development of new lesions, sometimes accompanied by neuritis [Ref- 2].</p>
            <p> ENL, or leprosy reaction type 2, is characterized by the clinical expression of systemic inflammation and neutrophil infiltration. The complement system is activated in the detected lesions and circulation, generating immune complexes, an increased CD4+/CD8+ T cell subsets ratio, and greater levels of the pro-inflammatory cytokine TNF-&#x03b1; [Ref-3]. Neutrophil infiltration has been found within the lesions during the acute phase of ENL. Antibodies that form immune complexes within tissues and blood vessels can cause type III hypersensitivity events, also known as immune complex-mediated hypersensitivity reactions [Ref- 4]. This condition causes fever symptoms in patients who experience ENL.</p>
            <p> In this case of a 41-year-old male patient, he had a ring-shaped fever rash, swelling, discomfort, and deformity of the limbs, along with intermittent fever lasting 16 days, with a body temperature over 39 &#x00b0;C. Upon physical examination, this patient suffered from ENL and presented with a flushed face and thin eyebrows, enlarged glands in the left cervical and inguinal lymph nodes, acromegaly with an eagle claw deformity on both hands, soft subcutaneous masses, keloid skin scars, and accompanying pigmentation. It was not specified if the patient had previously had multidrug therapy for leprosy. An aberrant hemogram with a 79.70% neutrophil percentage was seen upon laboratory evaluation. Ultrasonography revealed a subcutaneous lump in the right elbow joint, a sign of ENL on the skin.</p>
            <p> Type III hypersensitivity, called immune complex-mediated hypersensitivity, arises from inadequate elimination of immune complexes formed by binding antigens and antibodies to ENL. This causes an inflammatory reaction and mobilization of leukocytes. ENL patients show clinical manifestations of circulating immune complexes that specifically target phenolic glycolipid-1 (PGL-1) and primary cytosolic proteins of M. leprae. Neutrophils are important in the early stages of leprosy pathogenesis because they have a phagocytic function. The phagocytosis of M. leprae is followed by the release of pro-inflammatory mediators [Ref- 5]. Schwann cells showing type 2 leprosy reaction expression in leprosy lesions&#x00a0;undergo programmed cell death or apoptosis. This phenomenon may contribute to nerve damage in individuals suffering from leprosy [Ref-6]. However, nerve injury can occur without apoptosis or lysis. This phenomenon is caused by demyelination resulting from exposure to M. leprae without immune cells [Ref-7]. Therefore, apart from stopping the leprosy reaction as soon as possible in cases of ENL, it is considered necessary to provide MDT.</p>
            <p> Nevertheless, the exact mechanisms regarding the contribution of immune complexes to the development of ENL still need to be fully understood.</p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Yes</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Yes</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>Yes</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Dermatovenereology</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p>
        </body>
        <back>
            <ref-list>
                <title>References</title>
                <ref id="rep-ref-257374-1">
                    <label>1</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>Epidemiologic characteristics of leprosy reactions.</article-title>
                        <source>
                            <italic>Int J Lepr Other Mycobact Dis</italic>
                        </source>.<year>1994</year>;<volume>62</volume>(<issue>4</issue>) :<fpage>559</fpage>-<lpage>67</lpage>
                        <pub-id pub-id-type="pmid">7868954</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-2">
                    <label>2</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>High-resolution ultrasonography for early diagnosis of neural impairment in seropositive leprosy household contacts.</article-title>
                        <source>
                            <italic>PLoS One</italic>
                        </source>.<year>2023</year>;<volume>18</volume>(<issue>5</issue>) :
                        <elocation-id>10.1371/journal.pone.0285450</elocation-id>
                        <fpage>e0285450</fpage>
                        <pub-id pub-id-type="pmid">37220153</pub-id>
                        <pub-id pub-id-type="doi">10.1371/journal.pone.0285450</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-3">
                    <label>3</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression.</article-title>
                        <source>
                            <italic>J Infect Dis</italic>
                        </source>.<year>2003</year>;<volume>188</volume>(<issue>7</issue>) :
                        <elocation-id>10.1086/378410</elocation-id>
                        <fpage>1024</fpage>-<lpage>31</lpage>
                        <pub-id pub-id-type="pmid">14513423</pub-id>
                        <pub-id pub-id-type="doi">10.1086/378410</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-4">
                    <label>4</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>Erythema nodosum leprosum research: ENLISTing support.</article-title>
                        <source>
                            <italic>Lepr Rev</italic>
                        </source>.<year>2015</year>;<volume>86</volume>(<issue>4</issue>) :<fpage>304</fpage>-<lpage>6</lpage>
                        <pub-id pub-id-type="pmid">26964425</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-5">
                    <label>5</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>CR3 Engaged by PGL-I Triggers Syk-Calcineurin-NFATc to Rewire the Innate Immune Response in Leprosy</article-title>.
                        <source>
                            <italic>Frontiers in Immunology</italic>
                        </source>.<year>2019</year>;<volume>10</volume>:
                        <elocation-id>10.3389/fimmu.2019.02913</elocation-id>
                        <pub-id pub-id-type="doi">10.3389/fimmu.2019.02913</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-6">
                    <label>6</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy.</article-title>
                        <source>
                            <italic>Infect Immun</italic>
                        </source>.<year>2003</year>;<volume>71</volume>(<issue>3</issue>) :
                        <elocation-id>10.1128/IAI.71.3.1427-1433.2003</elocation-id>
                        <fpage>1427</fpage>-<lpage>33</lpage>
                        <pub-id pub-id-type="pmid">12595460</pub-id>
                        <pub-id pub-id-type="doi">10.1128/IAI.71.3.1427-1433.2003</pub-id>
                    </mixed-citation>
                </ref>
                <ref id="rep-ref-257374-7">
                    <label>7</label>
                    <mixed-citation publication-type="journal">
                        <person-group person-group-type="author"/>:
                        <article-title>Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells.</article-title>
                        <source>
                            <italic>Science</italic>
                        </source>.<year>2002</year>;<volume>296</volume>(<issue>5569</issue>) :
                        <elocation-id>10.1126/science.1067631</elocation-id>
                        <fpage>927</fpage>-<lpage>31</lpage>
                        <pub-id pub-id-type="pmid">11988579</pub-id>
                        <pub-id pub-id-type="doi">10.1126/science.1067631</pub-id>
                    </mixed-citation>
                </ref>
            </ref-list>
        </back>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report232288">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.152716.r232288</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Joy</surname>
                        <given-names>Nirma</given-names>
                    </name>
                    <xref ref-type="aff" rid="r232288a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-1987-5053</uri>
                </contrib>
                <aff id="r232288a1">
                    <label>1</label>MKCG Medical College and Hospital, Odisha, India</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>25</day>
                <month>5</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Joy N</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport232288" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.139440.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>I would like to suggest the case details mentioned are incomplete. With regarding to examination, please elaborate the skin findings, along with sites where seen, &#x00a0;sensations present or not, detailed motor, nerve examination, deformities present. please mention in detail about past history and drug history of anti leprosy of patient - duration , drugs , completed treatment or defaulter, years after completion of drugs. it would be great if condition of patient after anti leprosy treatment can be described like any Hansens symptoms persisting, any episodes of lepra reactions, if yes, number, duration and treatment given. also describe why patient was on prednisolone.&#x00a0;</p>
            <p> Always add recent epidemiological data. With development of medical technology and improvement of sanitary conditions, the World Health Organization set a goal of reducing leprosy prevalence to less than 1 per 10,000 inhabitants from 2000 to 2005.
                <sup>
                    <ext-link ext-link-type="uri" xlink:href="">6</ext-link>"</sup>
            </p>
            <p>Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?</p>
            <p>Partly</p>
            <p>Is the case presented with sufficient detail to be useful for other practitioners?</p>
            <p>Partly</p>
            <p>Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?</p>
            <p>No</p>
            <p>Is the background of the case&#x2019;s history and progression described in sufficient detail?</p>
            <p>Partly</p>
            <p>Reviewer Expertise:</p>
            <p>Hansens disease, childhood leprosy</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
    </sub-article>
</article>
